Access cutting-edge lung cancer treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.
Access lung cancer specialists in Houston at no cost
This study follows strict safety protocols and ethical guidelines
All study-related lung cancer treatment provided free
The goal of this First-In-Human (FIH) Phase I/II trial is to establish the safety profile, determine the Recommended Phase II Dose (RP2D), explore the pharmacokinetic (PK) exposure and pharmacodynamic (PD) properties as well as assess the efficacy of STX-241/PFL-241, a mutant selective Central Nervous System (CNS)-penetrant fourth generation EGFR TKI, in participants with locally advanced or metastatic NSCLC that progressed during or following third generation EGFR TKI such as osimertinib due to
Sponsor: Pierre Fabre Medicament
Check if you qualify for this lung cancer clinical trial in Houston, TX
If you're searching for lung cancer treatment options in Houston, TX, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.